BH3-only protein expression determines hepatocellular carcinoma response to sorafenib-based treatment

Hepatocellular carcinoma (HCC) represents a global health challenge with limited therapeutic options. Anti-angiogenic immune checkpoint inhibitor-based combination therapy has been introduced for progressed HCC, but improves survival only in a subset of HCC patients. Tyrosine-kinase inhibitors (TKI)...

Descripción completa

Detalles Bibliográficos
Autores principales: Busche, Stephanie, John, Katharina, Wandrer, Franziska, Vondran, Florian W. R., Lehmann, Ulrich, Wedemeyer, Heiner, Essmann, Frank, Schulze-Osthoff, Klaus, Bantel, Heike
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8313681/
https://www.ncbi.nlm.nih.gov/pubmed/34312366
http://dx.doi.org/10.1038/s41419-021-04020-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8313681/
https://www.ncbi.nlm.nih.gov/pubmed/34312366
http://dx.doi.org/10.1038/s41419-021-04020-z

Ejemplares similares